CA
TEVA icon

Calton & Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Calton & Associates’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-5,180
Closed -$108K – 1175
2017
Q4 		$108K Buy
+5,180
New +$77.9K 0.03% 472

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Calton & Associates's TEVA Position: Q1 2018 in Review

Calton & Associates sold out of Teva Pharmaceuticals (TEVA) in Q1 2018, closing a stake of 5,180 shares — an estimated $108K sold.

Calton & Associates first reported a position in TEVA in Q4 2017 and held it in 1 quarter. The position peaked at $108K in Q4 2017. 506 funds tracked by Wall St. Rank hold TEVA as of Q1 2018.

  • Calton & Associates reported no remaining Teva Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Calton & Associates sold 5,180 Teva Pharmaceuticals shares in Q1 2018, an estimated $108K.
  • Calton & Associates first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Calton & Associates's Teva Pharmaceuticals position peaked at $108K in Q4 2017.
  • 506 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.